“Ecstasy” (MDMA) Use

Total Page:16

File Type:pdf, Size:1020Kb

“Ecstasy” (MDMA) Use Louisa Degenhardt and Wayne Hall (editors) The health and psychological effects of “ecstasy” (MDMA) use NDARC Monograph No. 62 i ii THE HEALTH AND PSYCHOLOGICAL EFFECTS OF “ECSTASY (MDMA) USE” Louisa Degenhardt and Wayne Hall (editors) Monograph No. 62 ISBN: 978 0 7334 2862-3 ©NDARC 2010 Funded by the Australian National Government Department of Health Ageing, and by the Australian National Health and Medical Research Council iii For further information about this publication please contact: Louisa Degenhardt National Drug and Alcohol Research Centre University of New South Wales Sydney NSW 2052 AUSTRALIA Telephone: +61 (0)2 9385 0230 Facsimile: +61 (0)2 9382 0222 Email: [email protected] The citation for this report is as follows: Degenhardt, L., & Hall, W. (eds) (2010). The health and psychological effects of “ecstasy” (MDMA) use. National Drug and Alcohol Research Centre. University of New South Wales, Sydney. NDARC Monograph No. 62. iv Author affiliations Ross Beck National Drug and Alcohol Research Centre University of NSW Stuart Kinner Sydney NSW 2052 AUSTRALIA Senior Research Fellow & Deputy Director (Research) Raimondo Bruno Queensland Alcohol and Drug Research Lecturer and Education Centre (QADREC) School of Psychology School of Population Health University of Tasmania The University of Queensland GPO Box 252-30 Brisbane QLD 4072 Australia Hobart TAS 7001 AUSTRALIA Iain S. McGregor Paul Callaghan Professor of Psychopharmacology Radiopharmaceutical Research Institute ARC Australian Professorial Fellow Australian Nuclear Science and School of Psychology (A18) Technology Organisation University of Sydney PMB 1 Sydney NSW 2006 Australia Menai NSW 2234 AUSTRALIA Edmund Silins Louisa Degenhardt Doctoral Candidate/Senior Research Professor of Epidemiology Officer National Drug and Alcohol Research Centre National Drug and Alcohol Research Centre University of NSW University of NSW Sydney NSW 2052 AUSTRALIA Sydney NSW 2052 AUSTRALIA Jessica George Natasha Sindicich Research Officer Research Officer Queensland Alcohol and Drug Research National Drug and Alcohol Research Centre and Education Centre (QADREC) University of NSW School of Population Health Sydney NSW 2052 AUSTRALIA The University of Queensland Brisbane QLD 4072 Australia Libby Topp Senior Research Officer Wayne Hall Centre for Health Research in Criminal Professor of Public Health Policy Justice School of Population Health Suite 302, Level 2, Westfield Tower University of Queensland 152 Bunnerong Road Level 2 Public Health Building Pagewood NSW 2035 AUSTRALIA Herston Rd Herston, Queensland, 4006 v vi Table of contents UListU of tablesU................................................................................................................................................. viii UListU of figuresU ............................................................................................................................................... viii UAcknowledgementsU U ....................................................................................................................................... ix UGlossaryU U .......................................................................................................................................................... xi U1.U U UIntroductionU U ........................................................................................................................................... 1 ULouisaU Degenhardt and Wayne HallU .................................................................................................................... U2.U U UAssessingU the adverse health and psychological effects of MDMA (“ecstasy”) useU .................. 5 UWayneU HallU ......................................................................................................................................................... U3.U U UWhatU is “ecstasy”?U ............................................................................................................................... 16 ULouisaU Degenhardt and Natasha SindicichU ........................................................................................................... U4.U U UTheU epidemiology of ecstasy useU ...................................................................................................... 31 ULouisaU Degenhardt and Natasha SindicichU ........................................................................................................... U5.U U UTheU Psychopharmacology of MDMAU ............................................................................................. 48 UMurrayU R. Thompson, Paul D. Callaghan and Iain S. McGregorU ....................................................................... U6.U U UTheU acute effects of ecstasy (MDMA) useU ...................................................................................... 81 UEdmundU SilinsU ..................................................................................................................................................... U7.U U UDoesU MDMA use affect the immune and reproductive systems?U .............................................. 99 URossU BeckU ............................................................................................................................................................. U8.U U UIsU there an ecstasy (MDMA) dependence syndrome?U ................................................................ 115 ULouisaU Degenhardt, Raimondo Bruno and Libby ToppU ........................................................................................ U9.U U URelationshipsU between ecstasy use, the use of other drugs and mental disordersU .................. 134 ULouisaU Degenhardt, Wayne Hall, Jessica George and Stuart A. KinnerU ............................................................... U10.U U UTheU effects of ecstasy use upon cognitive functioningU ............................................................... 157 UEdmundU SilinsU ..................................................................................................................................................... U11.U U UMortalityU related to ecstasy (MDMA) useU ..................................................................................... 191 UEdmundU SilinsU ..................................................................................................................................................... U12.U U UTheU use of MDMA for therapeutic purposesU .............................................................................. 207 UNatashaU Sindicich, Louisa Degenhardt and Wayne HallU ..................................................................................... U13.U U USummaryU and implicationsU .............................................................................................................. 215 UWayneU Hall and Louisa DegenhardtU .................................................................................................................... vii List of tables UTableU 4.1: Prevalence of ecstasy use across countriesU .......................................................................... 39 UTableU 4.2: Prevalence of ecstasy use among young people across countriesU ................................... 40 UTableU 4.3: Patterns of use in regular ecstasy users in Australia, 2007U ................................................ 42 UTableU 8.1: DSM-IV dependence criteriaU ............................................................................................... 128 UTableU 8.2: Criteria for past year ICD-10 drug dependenceU ............................................................... 128 List of figures UFigureU 3.1: Usual locations of ecstasy use among regular ecstasy users in Australia, 2007U ............ 24 UFigureU 3.2: Tablets sold as “ecstasy”U ....................................................................................................... 26 UFigureU 3.3: Median number of pills typically taken in “average” and “heavy” use episodes by frequency of ecstasy use in the past six months among regular ecstasy users in Australia, 2007U . 28 UFigureU 4.1: Prevalence of ecstasy use in Australia, 1988-2004U ............................................................ 36 UFigureU 4.2: Prevalence of ecstasy use relative to other illicit drugs, Australia, 2004U........................ 37 UFigureU 4.3: Prevalence of lifetime and past year ecstasy use by age, Australia, 2004U ...................... 38 UFigureU 4.4: Prevalence of past year ecstasy use among high school students, United States, 1996- 2006U .............................................................................................................................................................. 40 UFigureU 4.5: Frequency of ecstasy use among past year users in Australia, 2004U .............................. 41 UFigureU 11.1: Number of ecstasy-related deaths nationally by level* of contribution to death, 2001 - 2004U .......................................................................................................................................................... 222 UFigureU 11.2: Ecstasy-related deaths by cause of death, 2001-4, AustraliaU ....................................... 222 viii Acknowledgements This work arose out of the increasing perception that there needed to be a summary of existing research on the epidemiology and possible effects of “ecstasy” (MDMA) use, given its increasing prevalence among young adults, and understandable
Recommended publications
  • Party Drug Papers Cover
    Dr ugs and Crime Prevention Committee Prevention ugs and Crime Drugs and Crime Prevention Committee Inquiry into Amphetamines and ‘Party Drug’ Use in Victoria Discussion Paper I nquiry into the Issue of Amphetamine & ‘Party Drug’ Use in Victoria in Use Drug’ Amphetamine & ‘Party nquiry of into the Issue Images courtesy of Kate Hiller from her video ‘Rave Culture’ – 2002. Amphetamines 5/9/03 5:25 PM Page i M E I A N L T R O A F P V I I A C T O R PARLIAMENT OF VICTORIA DRUGS AND CRIME PREVENTION COMMITTEE INQUIRY INTO AMPHETAMINE AND ‘PARTY DRUG’ USE IN VICTORIA September 2003 Amphetamines 5/9/03 5:54 PM Page ii SUBMISSIONS ARE INVITED The Committee welcomes written submissions in response to the issues raised in this Discussion Paper or on any matter related to the Terms of Reference of the Inquiry. To assist interested parties in making submissions a number of questions have been posed throughout the Discussion Paper. Details of how to make a Submission are included in the Insert. The Committee requires all submissions to be signed hard copy originals but would also appreciate an electronic copy. Submissions should be sent by Monday 13 October 2003 to: Inquiry into Amphetamine and ‘Party Drug’ Use in Victoria The Drugs and Crime Prevention Committee Level 8, 35 Spring Street, Melbourne Victoria 3000 Telephone: (03) 9651 3541 Facsimile: (03) 9651 3603 Email: [email protected] The Committee records its appreciation to Kate Hiller for permission to use images from her video Rave Culture 2002 in the artwork of this Discussion Paper.
    [Show full text]
  • Reforming Recreation Rob Whitehead Iowa State University, [email protected]
    Architecture Publications Architecture Spring 2014 Reforming Recreation Rob Whitehead Iowa State University, [email protected] Follow this and additional works at: http://lib.dr.iastate.edu/arch_pubs Part of the Architectural History and Criticism Commons The ompc lete bibliographic information for this item can be found at http://lib.dr.iastate.edu/ arch_pubs/67. For information on how to cite this item, please visit http://lib.dr.iastate.edu/ howtocite.html. This Article is brought to you for free and open access by the Architecture at Iowa State University Digital Repository. It has been accepted for inclusion in Architecture Publications by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Reforming Recreation Abstract A college campus is always in motion, and its students are rarely still. In this surrogate village, certain buildings have only a particular set of uses and users, so students are constantly moving around to find the av rious places, spaces, and faces that offer them the knowledge, rest, sustenance, and entertainment they need—ideally a little bit of each, conveniently offered in various locations, throughout their day. Disciplines Architectural History and Criticism Comments This article was originally published in the Iowa Architect magazine, the official magazine of the American Institute of Architects, Iowa Chapter. For more information contact AIA Iowa at 515.244.7502. This article is available at Iowa State University Digital Repository: http://lib.dr.iastate.edu/arch_pubs/67 words: rob whitehead, aia, leed ap images: dimension images architect: rdg planning & design recreation Iowa State's new student recreation building is centered on campus quality of life.
    [Show full text]
  • The Link Between Drugs and Music Explained by Science 25 January 2018, by Ian Hamilton, Harry Sumnall and Suzi Gage
    The link between drugs and music explained by science 25 January 2018, by Ian Hamilton, Harry Sumnall And Suzi Gage two key compounds in cannabis, tetrahydrocannabinol and cannabidiols, influence the desire for music and its pleasure. Cannabis users reported that they experienced greater pleasure from music when they used cannabis containing cannabidiols than when these compounds were absent. Listening to music – without the influence of drugs – is rewarding, can reduce stress (depending upon the type of music listened to) and improve feelings of belonging to a social group. But research Credit: Henny van Roomen/Shutterstock.com suggests that some drugs change the experience of listening to music. Clinical studies that have administered LSD to For centuries, musicians have used drugs to human volunteers have found that the drug enhance creativity and listeners have used drugs enhances music-evoked emotion, with volunteers to heighten the pleasure created by music. And the more likely to report feelings of wonder, two riff off each other, endlessly. The relationship transcendence, power and tenderness. Brain between drugs and music is also reflected in lyrics imaging studies also suggest that taking LSD while and in the way these lyrics were composed by listening to music, affects a part of the brain leading musicians, some of whom were undoubtedly to an increase in musically inspired complex visual influenced by the copious amounts of heroin, imagery. cocaine and "reefer" they consumed, as their songs sometimes reveal. Pairing music and drugs Acid rock would never have happened without Certain styles of music match the effects of certain LSD, and house music, with its repetitive 4/4 beats, drugs.
    [Show full text]
  • About Emotions There Are 8 Primary Emotions. You Are Born with These
    About Emotions There are 8 primary emotions. You are born with these emotions wired into your brain. That wiring causes your body to react in certain ways and for you to have certain urges when the emotion arises. Here is a list of primary emotions: Eight Primary Emotions Anger: fury, outrage, wrath, irritability, hostility, resentment and violence. Sadness: grief, sorrow, gloom, melancholy, despair, loneliness, and depression. Fear: anxiety, apprehension, nervousness, dread, fright, and panic. Joy: enjoyment, happiness, relief, bliss, delight, pride, thrill, and ecstasy. Interest: acceptance, friendliness, trust, kindness, affection, love, and devotion. Surprise: shock, astonishment, amazement, astound, and wonder. Disgust: contempt, disdain, scorn, aversion, distaste, and revulsion. Shame: guilt, embarrassment, chagrin, remorse, regret, and contrition. All other emotions are made up by combining these basic 8 emotions. Sometimes we have secondary emotions, an emotional reaction to an emotion. We learn these. Some examples of these are: o Feeling shame when you get angry. o Feeling angry when you have a shame response (e.g., hurt feelings). o Feeling fear when you get angry (maybe you’ve been punished for anger). There are many more. These are NOT wired into our bodies and brains, but are learned from our families, our culture, and others. When you have a secondary emotion, the key is to figure out what the primary emotion, the feeling at the root of your reaction is, so that you can take an action that is most helpful. .
    [Show full text]
  • MDMA and Sexual Behavior
    Note: This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Substance Use & Misuse following peer review. The definitive publisher-authenticated version [McElrath K (2005) MDMA and sexual behavior: ecstasy users’ perceptions about sexuality and sexual risk, Substance Use & Misuse, 40:9, 1461-1477] is available online at http://www.informaworld.com/smpp/title~db=all~content=g714012467 MDMA and Sexual Behavior: Ecstasy Users’ Perceptions About Sexuality and Sexual Risk KAREN MCELRATH School of Sociology and Social Policy, Belfast, Ireland Published in Substance Use & Misuse,(2005) 40:9,1461—1477 This study examines the relationship between MDMA (Ecstasy), sexual behavior, and sexual risk taking. The sample consisted of 98 current and former users of MDMA. Several strategies were utilized to recruit respondents and data were collected through in-depth interviews during 1997 and 1998. The majority of respondents had used MDMA during the 6-month period prior to the interview and a large percentage had consumed the drug on 100 occasions or more. Most respondents reported feelings of emotional closeness while consuming MDMA but without the desire for penetrative sex. Others, however, reported that MDMA increased sexual arousal and some respondents (in particular gay and bisexual females) had used MDMA specifically for sexual enhancement. Sexual risk taking (e.g., having multiple partners, engaging in sex without a condom) was prevalent among respondents who did engage in sexual activity during MDMA episodes. Explanations for the findings are offered and implications for prevention/intervention are discussed. Keywords MDMA; ecstasy; sexual behavior Introduction Although a patent for 3,4-methylenedioxymethamphetamine (MDMA) was issued in 1914 (Shulgin, 1986), “recreational”a use of the drug did not surface until the 1970s and 1980s, and for the most part was restricted to selected regions in the U.S.
    [Show full text]
  • Benefits of a Strong Parks and Recreation System
    A STRONG PARK AND RECREATION SYSTEM IS ESSENTIAL FOR A THRIVING COMMUNITY Four out of five North Americans use their local recreation and park system. 70% have a park or recreation facility within walking distance of their home. Our parks are such a stable influence on our lives that we tend not to give them much thought. But our effective parks and recreation facilities do not just happen on their own. They require professional care and financial support to keep them clean, safe and suitable for the community they serve. HEALTH BENEFITS: Access to parks and recreation facilities leads to healthy lifestyles for people of all ages. Strong evidence shows that when people have access to parks, they exercise more. Every time sedentary people walk a mile, they add 21 minutes to their life. On average, every hour you spend exercising increases your life expectancy by two hours. Exercise increases the brain’s capacity for learning. ENVIRONMENTAL BENEFITS: Parks, open spaces and trails play a key role in preserving water and air quality, reducing congestion and protecting wildlife. Through the provision of parks, open spaces and protected natural environment, recreation can contribute to the environmental health of our communities. Trail and pathway systems save energy and protect air quality by encouraging non-motorized transportation. COMMUNITY BENEFITS: Parks and Recreation sources give communities a vital identity. Well- maintained, accessible parks and recreation facilities are key elements of strong, safe, family-friendly communities. When citizens get involved with their parks and recreation systems, their quality of life improves. Parks and recreation opportunities encourage citizens to be engaged in their communities – as volunteers, stewards, advocates and students.
    [Show full text]
  • Eotm the Agony and the Ecstasy
    EYE ON THE MARKET SPECIAL EDITION THE & agTHE ny ecst sy THE RISKS AND REWARDS OF A CONCENTRATED StOCK POSITION The Agony and the Ecstasy is a 1961 biographical novel by American author Irving Stone on the life of Michelangelo: his passion, intensity and perseverance as he created some of the greatest works of the Renaissance period. Like Michelangelo’s paintings and sculptures, successful businesses are the by-product of inspiration, hard work, and no small amount of genius. And like the works of the Great Masters, only a small minority stand the test of time and last over the long run. The Agony and the Ecstasy conveys the disparate outcomes facing concentrated holders of individual stocks in a world, like Michelangelo’s, that is beset with intrigue, unforeseen risks, intense competition and uncertainty. EYE ON THE MARKET • J.P. MORGAN Eye on the Market J.P. MORGAN The Agony and the Ecstasy: The Risks and Rewards of a Concentrated Stock Position Executive Summary There are many Horatio Alger stories in the corporate world in which an entrepreneur or CEO has the right idea at the right time and executes brilliantly on a business plan. But history also shows that forces both within and outside management control led many of their businesses to suffer serious reversals of fortune. As a result, many individuals are known not just for the wealth they created through a concentrated position, but also for the decision they made to sell, hedge or otherwise take some chips off the table. In this paper, we take a look at the long history of individual stocks, and at the risks and rewards of concentration.
    [Show full text]
  • Special Recreation Management Areas
    Appendix E Special Recreation Management Areas Final Environmental Impact Statement Table of Contents Introduction .......................................................................................................................................... 1 Cortez Special Recreation Management Area................................................................................... 1 Dolores River Special Recreation Management Area ...................................................................... 7 Durango Special Recreation Management Area ............................................................................. 13 Silverton Special Recreation Management Area ............................................................................ 17 Figure E-1. Cortez SRMA ..................................................................................................................... 21 Figure E-2. Dolores River SRMA .......................................................................................................... 22 Figure E-3. Durango SRMA .................................................................................................................. 23 Figure E-4. Silverton SRMA .................................................................................................................. 24 Volume III Appendix E – Special Recreation Management Areas E-i San Juan National Forest Final Land and Resource Management Plan Tres Rios Field Office Proposed Land and Resource Management Plan This page intentionally left blank. Volume
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • Effect of Repeated MDMA Exposure on Rat Brain and Behaviour
    Effect of repeated MDMA exposure on rat brain and behaviour by Ross van de Wetering A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy Victoria University of Wellington, New Zealand 2020 Table of contents Absract ........................................................................................................................... 5 List of abbreviations ...................................................................................................... 7 CHAPTER 1: GENERAL INTRODUCTION ............................................................ 10 Introduction ........................................................................................................................ 10 Behavioural fundamentals of addiction ........................................................................... 12 Studying addiction ........................................................................................................... 13 Self-administration. ...................................................................................................... 14 Behavioural sensitisation. ............................................................................................ 18 Neurocircuitry of addiction ............................................................................................... 20 Ventral tegmental area and nucleus accumbens .............................................................. 20 Dopamine and reinforcement. .....................................................................................
    [Show full text]
  • Clinical Trial of the Neuroprotectant Clomethiazole in Coronary Artery Bypass Graft Surgery a Randomized Controlled Trial Robert S
    Anesthesiology 2002; 97:585–91 © 2002 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Clinical Trial of the Neuroprotectant Clomethiazole in Coronary Artery Bypass Graft Surgery A Randomized Controlled Trial Robert S. Kong, F.R.C.A.,* John Butterworth, M.D.,† Wynne Aveling, F.R.C.A.,‡ David A. Stump, M.D.,† Michael J. G. Harrison, F.R.C.P.,§ John Hammon, M.D.,ʈ Jan Stygall, M.Sc.,# Kashemi D. Rorie, Ph.D.,** Stanton P. Newman, D.Phil.†† Background: The neuroprotective property of clomethiazole THE efficacy of coronary artery bypass surgery in the has been demonstrated in several animal models of global and relief of angina and in some circumstances in enhancing Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/97/3/585/335909/0000542-200209000-00011.pdf by guest on 29 September 2021 focal brain ischemia. In this study the authors investigated the life expectation is now accepted. It is a tribute to the low effect of clomethiazole on cerebral outcome in patients under- mortality of the procedure that interest is now focused going coronary artery bypass surgery. Methods: Two hundred forty-five patients scheduled for on the neurologic and neuropsychological complica- 1–3 coronary artery bypass surgery were recruited at two centers tions. Adverse neurologic outcomes have been found and prospectively randomized to clomethiazole edisilate to occur in 2–6% of patients and neuropsychological (0.8%), 225 ml (1.8 mg) loading dose followed by a maintenance deficits in 10–30%.4–6 These complications are consid- dose of 100 ml/h (0.8 mg/h) during surgery, or 0.9% NaCl ered to be ischemic in nature, being a consequence of (placebo) in a double-blind trial.
    [Show full text]
  • A Retrospective Comparison of Inappropriate Prescribing Of
    Schjøtt and Aßmus BMC Medical Informatics and Decision Making (2019) 19:102 https://doi.org/10.1186/s12911-019-0821-0 RESEARCHARTICLE Open Access A retrospective comparison of inappropriate prescribing of psychotropics in three Norwegian nursing homes in 2000 and 2016 with prescribing quality indicators Jan Schjøtt1,2* and Jörg Aßmus3 Abstract Background: Inappropriate prescribing of psychotropics is a persistent and prevalent problem in nursing homes. The present study compared inappropriate prescribing of psychotropics in nursing homes 16 years apart with prescribing quality indicators. The purpose was to identify any change in inappropriate prescribing of relevance for medical informatics. Methods: Three Norwegian nursing homes were audited in 2000 and 2016 with regard to prescribing quality. Psychotropics among 386 patients in 2000, and 416 patients in 2016, included combinations of antidepressants, antipsychotics, anxiolytics-hypnotics, and antiepileptics. Prescribing quality indicators included psychotropic polypharmacy (defined as concurrent use of three or more psychotropics) and potential inappropriate psychotropic substances or combinations. Furthermore, potential clinically relevant psychotropic interactions were classified as pharmacodynamic or pharmacokinetic using an interaction database. The first ranked (most important) interaction in each patient was selected with the following importance of categories in the database; recommended action > documentation > severity. Three levels (from low to high) within each category were used for ranking. Results: From 2000 to 2016, psychotropic polypharmacy increased from 6.2 to 29.6%, potential inappropriate psychotropic substances was reduced from 17.9 to 11.3% and potential inappropriate psychotropic combinations increased from 7.8 to 27.9%. Changes in polypharmacy and combinations were predominantly associated with prescribing of anxiolytics-hypnotics.
    [Show full text]